Ipsen CEO Talks Rare Disease Therapeutic Development and the Risks of Gene Therapy

David Loew, CEO of Ipsen, spoke at the JP Morgan Healthcare Conference about his outlook on the rare disease field. Loew noted that Ipsen was leaning into the market full-steam, regardless of pressure from Big Pharma companies attempting to crowd the space. That said, the CEO was more cautious on the gene therapy and neuroscience fronts.

According to Angus Liu, “Specifically, he said Ipsen will focus on niche conditions rather than large indications like Alzheimer’s disease. In this space, Ipsen expects phase 2b/3 readout for mesdopetam soon this year. Ipsen got the drug mid-2021 through a deal with Swiss company IRLAB, and the targeted indication is for uncontrolled movements in Parkinson’s disease patients.”

To read more, click here.

(Source: Fierce Pharma, January 18^th, 2022)